Association between progression-free survival (PFS) rate (PFSR) and overall survival (OS) in LUME-Meso, a study of nintedanib (N) vs. placebo (P) in combination with first-line pemetrexed/cisplatin (PEM/CIS) in patients (pts) with malignant pleural mesothelioma (MPM). Meeting Abstract

Industry Collaboration International Collaboration

cited authors

  • Pavlakis, Nick; Grosso, Federica; Steele, Nicola L.; Nowak, Anna K.; Novello, Silvia; Popat, Sanjay; Greillier, Laurent; Reck, Martin; John, Tom; Taylor, Paul; Leighl, Natasha B.; Ceresoli, Giovanni Luca; Sorensen, Jens Benn; Planchard, David; Hughes, Brett Gordon Maxwell; Mazieres, Julien; Socinski, Mark A.; von Wangenheim, Ute; Barrueco, Jose; Scagliotti, Giorgio V.

authors

Publication Date

  • May 20, 2018

webpage

published in

category

volume

  • 36

issue

  • 15